Top

Published in:

01-05-2012 | Original article

SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?

Authors: G. Gerasimou, D. C. Costa, E. Papanastasiou, S. Bostanjiopoulou, M. Arnaoutoglou, E. Moralidis, T. Aggelopoulou, A. Gotzamani-Psarrakou

Published in: Annals of Nuclear Medicine | Issue 4/2012

Abstract

Objectives

The differential diagnosis between essential tremor (ET) and Parkinson’s disease (PD) may be, in some cases, very difficult on clinical grounds alone. In addition, it is accepted that a small percentage of ET patients presenting symptoms and signs of possible PD may progress finally to a typical pattern of parkinsonism. Ioflupane, N-u-fluoropropyl-2a-carbomethoxy-3a-(4-iodophenyl) nortropane, also called FP-CIT, labelled with ¹²³I (commercially known as DaTSCAN) has been proven to be useful in the differential diagnosis between PD and ET and to confirm dopaminergic degeneration in patients with parkinsonism. The aim of this study is to identify dopaminergic degeneration in patients with PD and distinguish them from others with ET using semi-quantitative SPECT ¹²³I-Ioflupane (DaTSCAN) data in comparison with normal volunteers (NV), in addition with the respective ones of patients referred as suffering from ET, as well as, of patients with a PD diagnosis at an initial stage with a unilateral presentation of motor signs.

Methods

Twenty-eight patients suffering from ET (10 males plus 18 females) and 28 NV (12 males and 16 females) were enroled in this study. In addition, 33 patients (11 males and 22 females) with an established diagnosis of PD with unilateral limb involvement (12 left hemi-body and 21 right hemi-body) were included for comparison with ET. We used DaTSCAN to obtain SPECT images and measure the radiopharmaceutical uptake in the striatum (S), as well as the caudate nucleus (CN) and putamen (P) in all individuals.

Results

Qualitative (Visual) interpretation of the SPECT data did not find any difference in the uptake of the radiopharmaceutical at the level of the S, CN and P between NV and ET patients. Reduced accumulation of the radiopharmaceutical uptake was found in the P of all PD patients. Semiquantitative analysis revealed significant differences between NV and ET patients in the striatum, reduced in the latter. There was also a significant reduction in the tracer accumulation in the left putamen of patients with right hemi-parkinsonism compared to ET and NV. Patients with left hemi-parkinsonism, demonstrated reduced radioligand uptake in the right putamen in comparison with ET and NV. Clinical follow-up of 20 patients with ET at (so many months afterwards) revealed no significant change in clinical presentation, particularly no signs of PD. Follow-up DaTSCAN performed in 10 of them (so many months afterwards) was negative in all but one. This one had an equivocal baseline study which deteriorated 12 months later.

Conclusions

Our results do not support the hypothesis of a link between essential tremor and Parkinson’s disease. However, it appears that ET patients have a small degree of striatal dopaminergic degeneration. If this is due to alterations in the nigrostriatl pathway or of other origin it is not clear. Follow-up studies of essential tremor patients are warranted to assess progression of disease and to understand better the possible cause for striatal dopaminergic degeneration.

Bernheimer H, Birkmayer W, Hornykiewitz O, Jelinger K, Seitleberger F. Brain dopamine damage and the syndromes of Parkinson and Huntington. J Neurol Sci. 1973;20:415–55.PubMedCrossRef

Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s disease striatum. Synapse. 1991;9:43–9.PubMedCrossRef

Larsen TA, Calne DB. Essential tremor. Clin Neuropharmacol. 1983;6:185–206.PubMedCrossRef

Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing. 1999;28:99–102.PubMedCrossRef

Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson’s disease. Arch Neurol. 2000;57:369–72.PubMedCrossRef

Quinn N. Parkinsonism-recognition and differential diagnosis. BMJ. 1995;310:447–52.PubMedCrossRef

Cleeves L, Findley LJ, Koller W. Lack of association between essential tremor and Parkinson’s disease. Ann Neurol. 1988;24:23–6.PubMedCrossRef

Errea-Abad JM, Ara-Callizo JR. Comparative clinical study of patients with Parkinson’s disease and essential tremor. Rev Neurol. 1998;27:39–43.PubMed

Minen MT, Louis ED. Emergence of Parkinson’s disease in essential tremor: a study of the clinical correlates in 53 patients. Mov Disord. 2008;23:1602–5.PubMedCrossRef

10.

Tan EK, Lee SS, Fook-Chong S, Lum SY. Evidence of increased odds of essential tremor in Parkinson’s disease. Mov Disord. 2008;23:993–7.PubMedCrossRef

11.

Louis ED, Frucht SJ. Prevalence of essential tremor in patients with Parkinson’s disease vs Parkinson-plus syndromes. Mov Disord. 2007;30(22):1402–7.CrossRef

12.

Chaudhuri KR, Buxton-Thomas M, Dhawan V, Peng R, Meilak C, Brooks DJ. Long duration asymmetrical postural tremor is likely to predict development of Parkinson’s disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry. 2005;76:115–7.PubMedCrossRef

13.

Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:67–76.PubMedCrossRef

14.

Jankovic J, Beach J, Schwartz K, Contant C. Tremor and longevity in relatives of patients with Parkinson’s disease, essential tremor, and control subjects. Neurology. 1995;45:645–8.PubMedCrossRef

15.

Yahr MD, Orosz D, Purohit DP. Co-occurrence of essential tremor and Parkinson’s disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord. 2003;9:225–31.PubMedCrossRef

16.

Ondo WG, Lai D. Olfaction testing in patients with tremor-dominant Parkinson’s disease: is this a distinct condition? Mov Disord. 2005;20:471–5.PubMedCrossRef

17.

Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, et al. Increased risk of essential tremor in first-degree relatives of patients with Parkinson’s disease. Mov Disord. 2007;22:1607–14.PubMedCrossRef

18.

Booij J, Speelman JD, Horstnink MWIM, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with 123I-FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–72.PubMedCrossRef

19.

Gerasimou G, Tsolaki M, Bonstanjopoulou S, Liaros G, Papanastasiou E, Balaris V, et al. Findings from molecular imaging with SPET camera and 123I-Ioflupane in the differential diagnosis of Parkinsonism and essential tremor. Hell J Nucl Med. 2005;8:81–5.PubMed

20.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stool JC, Janssen AG, et al. 123I-β-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:133–40.PubMedCrossRef

21.

Berendse HW, Booij J, Stoffers D, Ponsen MM, Hijman R, Wolters EC. Presymptomatic detection of Parkinson’s disease. Tijdschr Gerontol Geriatr. 2002;33:70–7.PubMed

22.

Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, et al. Measurement of dopamine degeneration in Parkinson’s disease with 123I-b-CIT and SPECT correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm. 1997;S50:9–24.

23.

Catafau A, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;19:1175–82.PubMedCrossRef

24.

Gerasimou GP, Aggelopoulou TC, Costa DC, Gotzamani-Psarrakou A. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders. Nucl Med Rev. 2006;9:147–53.

25.

Deuschi G, Bain P, Brin M, Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998;13(Suppl 3):2–23.

26.

Booij J, Hemelaar JTGM, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal pathway in Parkinson’s disease by 123I-FPCIT SPECT. J Nucl Med. 1999;40:753–61.PubMed

27.

Elbie RJ. Report from a US conference on essential tremor. Mov Disord. 2006;21:2052–61.CrossRef

28.

Jenkins IH, Bain PG, Colebatch JG, Thompson PD, Findley LJ, Frackowiak RS, et al. A positron emission tomography study fro overactivity of cerebellar connections. Ann Neurol. 1993;34:82–90.PubMedCrossRef

29.

Deuschi G, Wienzelburger R, Löffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction. Clinical and kinematic analysis of intention tremor. Brain. 2000;123:1568–80.CrossRef

30.

Lou RS, Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord. 1991;41:234–8.

31.

Antonini A, De Notaris R. PET and SPECT functional imaging in Parkinson’s disease. Sleep Med. 2004;5:201–6.PubMedCrossRef

32.

Lee MS, Kim YD, Im JH, Kim HJ, Rinne JO, Bhatia KP. ¹²³I-IPT brain SPECT study in essential tremor and Parkinson’s disease. Neurology. 1999;52:1422–6.PubMedCrossRef

33.

Schwarz M, Groshar D, Inzelberg R, Hocheman S. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities of detection of early Parkinson’s disease. Parkinsonism Relat Disord. 2004;10:385–9.CrossRef

34.

Isaias I, Canesi M, Benti R, Gerundini P, Cilia R, Pezzoli G, et al. Striatal dopamine transporter abnormalities in patients with essentail tremor. Nucl Med Commun. 2008;29:349–53.PubMedCrossRef

35.

Louis ED, Honing LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathological study. Ann Neurol. 2005;62:1004–7.CrossRef

36.

Djialdetti R, Nageris BI, Lorberboym M, Treves TA, Melamed E, Yaniv E, et al. [¹²³I]-FP-CIT APSECT and olfaction test in patients with combined postural and rest tremor. J Neural Transm. 2008;115:469–72.CrossRef

37.

Brooks DJ, Playford ET, Ibanez V, Sawle GV, Thompson PD, Findley LJ, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an ¹⁸F-dopa study. Neurology. 1992;42:1554–60.PubMedCrossRef

38.

Breit S, Reimold M, Reishl G, Klockgether T, Wüllner U. [¹¹C]d-threo-methyphenidate PET in patients with Parkinson’s disease and essential tremor. J Neural Transm. 2006;113:187–93.PubMedCrossRef

39.

Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brücke T. [¹²³I]β-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm. 1998;105:1213–28.PubMedCrossRef

40.

Isaias IU, Canesi M, Benti R, Canesi M, Marotta G, Gerundini P, et al. [¹²³I]FP-CIT striatal binding in early Parkinson’s disease patients with tremor dominant vs. akinetic-rigid onset. Neuroreport. 2007;18:1499–502.PubMedCrossRef

41.

Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhief A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521–30.PubMed

42.

Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2 receptors in human striatum. Synapse. 2009;63:282–90.PubMedCrossRef

Title: SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?
Authors: G. Gerasimou
D. C. Costa
E. Papanastasiou
S. Bostanjiopoulou
M. Arnaoutoglou
E. Moralidis
T. Aggelopoulou
A. Gotzamani-Psarrakou
Publication date: 01-05-2012
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 4/2012
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-012-0577-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Usefulness of extent analysis for statistical parametric mapping with asymmetry index using inter-ictal FGD-PET in mesial temporal lobe epilepsy

Prognostic implications of microscopic involvement of surgical resection margin in patients with differentiated papillary thyroid cancer after high-dose radioactive iodine ablation

Pulmonary function–morphologic relationships assessed by SPECT–CT fusion images

Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy

CT tube current for attenuation map in a combined PET/CT system: obese patient simulated phantom study

Outpatient therapeutic nuclear oncology